Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.96%

25/03	North American Morning Briefing : Tech in Focus on -2-	DJ
25/03	Infinity Pharmaceuticals, Inc. Went Out of Business	CI

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

September 29, 2023 at 09:30 am IST

Infinity Pharmaceuticals, Inc along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on September 29, 2023. The debtor listed its assets of $0.19 million and liabilities of $5.53 million. The debtor is represented by Matthew B. McGuire and Matthew R Pierce of Landis Rath & Cobb LLP and Wilmer Cutler Pickering Hale and Dorr LLP as its legal counsel.

The debtor also hired Sonoran Capital Advisors, LLC as financial advisor, SSG Advisors, LLC as investment banker, and Stretto, Inc of notice and claims agent.

Latest news about Infinity Pharmaceuticals, Inc.

North American Morning Briefing : Tech in Focus on -2-	25/03	DJ
Infinity Pharmaceuticals, Inc. Went Out of Business	25/03	CI
Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	07/03	CI
Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc.	22/02	CI
An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	15/02	CI
First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc.	13/02	CI
Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc.	01/02	CI
First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc.	26/01	CI
North American Morning Briefing : Tech Likely to -2-	19/01	DJ
North American Morning Briefing : Stock Futures Waver Ahead of Bank-Earnings Bonanza	12/01	DJ
Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc.	11/01	CI
Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc.	08/01	CI
North American Morning Briefing : Bond Yields Rise -2-	05/01	DJ
North American Morning Briefing : Stock Futures Gain as 2023 Draws to a Close	29/12	DJ
North American Morning Briefing : Stock Futures -2-	18/12	DJ
North American Morning Briefing : Investors Await -2-	11/12	DJ
North American Morning Briefing : Stock Futures, -2-	04/12	DJ
North American Morning Briefing : Stock Futures -2-	27/11	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	20/11	DJ
North American Morning Briefing : Stock Futures -2-	13/11	DJ
Bidding Procedure Approved for Infinity Pharmaceuticals, Inc.	23/23/23	CI
Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc.	02/23/02	CI
Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board	30/23/30	CI
INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI…	29/23/29	RE
Motion for Asset Sale Filed by Infinity Pharmaceuticals, Inc.	29/23/29	CI

Chart Infinity Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
INFINITY PHARMACEUTICALS, INC.	-99.96%	90
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research